J&J Defends Duragesic, Ortho Evra Patches
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety of transdermal delivery system is not undermined by recent reports of adverse events with the products, the firm says. Mylan defends its own transdermal fetanyl patch, stating that FDA safety review pertains to Duragesic.
You may also be interested in...
Ortho-McNeil Faces $150 Mil. Wrongful Death Suit Over Ortho Evra
Lawsuit alleges 17-year-old woman died from blood clots as a result of wearing the Ortho Evra patch.
Ortho-McNeil Faces $150 Mil. Wrongful Death Suit Over Ortho Evra
Lawsuit alleges 17-year-old woman died from blood clots as a result of wearing the Ortho Evra patch.
Ortho-McNeil Conducting Additional Studies To Assess Ortho Evra Blood Clotting Risks
The firm updated labeling to include a new bolded warning regarding increased hormone exposure with the patch versus oral contraceptives.